Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML

NCT05404516 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Core Binding Factor Acute Myeloid Leukemia

Interventions

DRUG: Sorafenib
DRUG: Idarubicin
DRUG: Cytarabine

Sponsor

Nanfang Hospital, Southern Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]